BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. Source
No articles found.
Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...
Vaccinex is a clinical-stage biotechnology comp...
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...
Gritstone Oncology is developing tumor-specific...
Robovet Corporation has developed a new MR imaging technology that can also help t...
Robovet Corporation has developed a new MR imag...
Helius Medical Technologies, Inc. (Helius) is a neurotech company in the medical d...
Helius Medical Technologies, Inc. (Helius) is a...
We are a biotechnology company focused on delivering transformational therapies fo...
We are a biotechnology company focused on deliv...
Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical...
Neurocrine Biosciences (Nasdaq: NBIX) is a neur...
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lu...
Biocept, Inc. is a molecular diagnostics compan...
Join the National Investor Network and get the latest information with your interests in mind.